Medication Study for the Treatment of Agitation in Moderate to Severe Alzheimer's Disease
Description: The purpose of this study is to determine whether an investigational medication (ELND005) is effective for reducing behaviors in people with moderate to severe Alzheimer's disease who have agitation/aggression.
Study Length: 12 Weeks
Study Requirements
- Diagnosis of moderate to severe Alzheimer's disease with behavior problems/agitation.
- A study partner who will accompany the participant to all clinic visits.
Objective Evaluation of Family Caregiving Study
Description: The goal of this study is to learn how family caregivers deal with dementia-related behavior and how they respond to suggestions for handling these situations at home. Participants will be asked to wear a video device at home to capture daily interactions with their family member with dementia.
Study Length: 3-4 months
Study Requirements
- Family caregiver age 21 or older who lives with and provides care to a person with moderate to severe dementia
- Person age 50 or older with moderate or severe dementia whose behavior is difficult for the caregiver
- Willing to engage in all study activities at home and by phone
The Recall Study (Retaining Cognition while Avoiding Late-Life Depression)
Description: This research project will test whether Problem Solving Therapy (PST) is successful in preventing major depression for those living with mild cognitive impairments. We will also examine the effect of modest exercise on mood.
Study Requirements: Individuals 60 years and older with a diagnosis of Mild cognitive impairment.
Study length: 8-12 weeks of PST sessions and follow up visits at 3 month intervals for 12 months.
Contact: MaryAnn Oakley at 412-692-2721 or oakleym@upmc.edu
Alzheimer Disease Neuroimaging Study 2 – (ADNI2)
Description: The goal of this study is to determine whether imaging of the brain (through MRI, PET and amyloid imaging scans) can help predict the onset and monitor the progression of cognitive change. The study will test blood and cerebrospinal fluid (from lumbar punctures) to determine if biomarkers can predict and monitor the disease.
Study Length: 54 months
Study Requirements:
- Between 55 and 90 years of age
- Study partner to accompany to all clinical visits
- Either have a diagnosis of early Alzheimer's disease or Mild Cognitive Impairment (MCI).